Abstract
Oncogenic osteomalacia is a rare paraneoplastic syndrome. It is characterized by bone pain, muscle weakness, gait disturbance, fractures and skeletal deformities. Hypophosphatemia, diminished renal phosphate reabsorption, decreased 1,25 dihydroxy Vitamin D and elevated alkaline phosphatase are the biochemical hallmarks of this disorder. Most tumors are of mesenchymal origin. We report the case of a 39-yearold woman with oncogenic osteomalacia caused by osteosarcoma of the right scapula which was unrecognized for several years. She subsequently developed tertiary hyperparathyroidism after treatment with oral phosphate and Vitamin D. This case illustrates that oncogenic osteomalacia may persist for many years before the tumor is discovered. This is because the tumors are frequently very small and are in obscure locations. The uniqueness of this case is the coexistence of hyperparathyroidism and oncogenic osteomalacia. Five other cases have been reported up to date. All patients had received phosphate supplement, ranging from 10 to 14 years prior to their diagnosis. Interestingly, our patient was on the treatment for only 2 years. The proposed mechanism is that exogenous phosphate stimulates parathyroid activity through sequestration of calcium.
This is a preview of subscription content, log in via an institution to check access.
References
Glorieux F.H., Scriver C.R., Reade T.M., Doldman T.M., Roseborough A. Use of phosphate and Vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N. Engl. J. Med. 1972, 287: 481–487.
Firth R.G., Grant C.S., Riggs B.L. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia Am. J. Med. 1985, 75: 669–673.
Rivkees S.A., El-Hajj-Fuleiham G., Brown E.M., Crawford J.D. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 1992, 75: 1514–1521.
Naevaez J., Rodriguez-Moremo J., Moragues C., Campoy E., Clavaguera T. Tertiary hyperparathyroidism after long-term supplementation in adult-onset hypophosphatemic osteomalacia. J. Bri. Rheuma. 1996, 35: 598–600.
Teasell R.W., Sue-A-Quan G., Wolfe B.M. Osteomalacia as a cause of chronic pain. Pain Res. Manage 1996, 1: 69–72.
McCance R.A. Osteomalacia with looser’s nodes due to a raised resistance to vitamin D acquired about the age of 15 years. Am. J. Med. 1947, 16: 33–46.
Prader A., Illig R., Uehlinger R.E., Stalder G. Rachitis lnfolge knochentumors. Helvet. Pediatr. Acta 1959, 14: 554–565.
Sweet R.A., Males J.L., Hamstra A.J., DeLuca H.F. Vitamin D metabolite level in oncogenic osteomalacia. Ann. Intern. Med. 1980, 93: 279–280.
Nakahama H., Nakanishi T.L., Uno H., Taji N., Uymam O. et al. Prostate cancer-induced oncogenic hypophosphatemia osteomalacia. Urol. Int. 1995, 55: 38–40.
Taylor H., Fallen M.D., Velasco M.E. Oncogenic osteomalacia: an inappropriate hormone secretion due to an oat cell carcinoma. Ann. Intren. Med. 1994, 101: 786–788.
Cai Q., Hoodoson S., Kao P., Lennon V.A., Klee G.G., Zinsiemster A.R., Kumar R. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with osteogenic osteomalacia. N. Engl. J. Med. 1994, 330: 1645–1649.
Wilkins G.E., Granleese S., Hegele R.G., Anderson D.W., Bondy G.P. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J. Clin. Endocrinol. Metab. 1995, 80: 1628–1634.
Meyer R.A., Meyer M.H., Gray R.W. Parabiosis suggests a humoral factor is involved in x-linked hypophosphatemia in mice. J. Bone Miner. Res. 1989, 4: 493–500.
Miyauchi A., Fukase M., Tsutsumi M., Fujita T. Hemangiopericytoma-induced osteomalacia: tumoltransplantation in nude mice causes hypophosphatemia and tumor extract inhibits renal 25-hydroxyvitamin D-1-hydroxylase. J. Clin. Endocrinol. Metab. 1988, 61: 46–53.
Murer H. Cellular mechanism in proximal tubular Pi absorption: some answers and more questions. J. Am. Soc. Nephrol. 1992, 21: 1649–1665.
Olefsky J., Kempson R., Jones H., Reaven G. Tertiary hyperparathyroidism and apparent cure of Vitamin-D-resistant rickets after removal of an ossifying mesenchymal tumor of the pharynx. N. Engl. J. Med. 1972, 286: 740–745.
Glanville H.J., Bloom R. Case of renal tubular osteomalacia (Dent Type 2) with later development of autonomous parathyroid tumor Br. Med. J. 1965, 2: 26–29.
Wyman A.L., Paradinas F.J., Daly J.R. Hypophosphatemic osteomalacia associated with a malignant tumor of the tibia: report of a case. J. Clin. Pathol. 1977, 30: 328–335.
Reid I.R., Teitelbaum S.L., Dusso A., Whyte M.P. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Am. J. Med. 1987, 83: 350–354.
Ryan R.A., Reiss E. Oncogenic osteomalacia. Am. J. Med. 1984, 77: 501–512.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, Q.L., Feig, D.S. & Blackstein, M.E. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest 23, 263–267 (2000). https://doi.org/10.1007/BF03343720
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343720